MyFinsight
Home
Compare
About
Recent SEC Filings
10/2
NIKE, Inc.
(NKE)
10/2
DARDEN RESTAURANTS INC
(DRI)
9/30
CONAGRA BRANDS INC.
(CAG)
9/29
Carnival Corp Ltd.
(CCL)
9/29
URANIUM ENERGY CORP
(UEC)
9/29
COPART INC
(CPRT)
9/24
BLACKBERRY Ltd
(BB)
9/24
PAYCHEX INC
(PAYX)
9/23
GENERAL MILLS INC
(GIS)
9/22
ADOBE INC.
(ADBE)
9/18
KROGER CO
(KR)
10/2
NIKE, Inc.
(NKE)
10/2
DARDEN RESTAURANTS INC
(DRI)
9/30
CONAGRA BRANDS INC.
(CAG)
9/29
Carnival Corp Ltd.
(CCL)
9/29
URANIUM ENERGY CORP
(UEC)
9/29
COPART INC
(CPRT)
9/24
BLACKBERRY Ltd
(BB)
9/24
PAYCHEX INC
(PAYX)
9/23
GENERAL MILLS INC
(GIS)
9/22
ADOBE INC.
(ADBE)
9/18
KROGER CO
(KR)
PMCB Balance Sheet Sankey Diagram
Sankey diagram visualizing PMCB balance sheet for the period
Cash and cash
equivalents
$17,738,991
(34.61%↑ Y/Y)
Investment in preferred
stock - qcls - current
$12,675,000
Dividends receivable
$429,150
Marketable equity
securities
$99,462
(-62.02%↓ Y/Y)
Prepaid expenses and
other current assets
$32,004
(-86.56%↓ Y/Y)
Warrant asset qcls non
current
$5,664,000
(90.96%↑ Y/Y)
Warrant asset femasys
$66,000
(-96.42%↓ Y/Y)
Other assets
$7,688
(0.00%↑ Y/Y)
Total current assets
$30,974,607
(62.12%↑ Y/Y)
Total other assets
$5,737,688
(-77.94%↓ Y/Y)
Total assets
$36,712,295
(-18.62%↓ Y/Y)
Total liabilities,
temporary equity and...
$36,712,295
(-18.62%↓ Y/Y)
Total stockholders
equity
$27,508,504
(-36.89%↓ Y/Y)
Total liabilities
$6,896,682
(354.07%↑ Y/Y)
Total temporary
equity
$2,307,109
Accumulated deficit
-$109,474,805
(-17.30%↓ Y/Y)
Treasury stock, at cost,
15,270,066 shares as of july...
$45,009,541
(0.90%↑ Y/Y)
Accumulated other
comprehensive loss
-$21,411
(9.83%↑ Y/Y)
Additional paid-in capital
$182,011,659
(0.25%↑ Y/Y)
Total other
liabilities
$6,128,000
(1237.99%↑ Y/Y)
Total current
liabilities
$768,682
(-27.54%↓ Y/Y)
Convertible preferred stock
$1,890,109
Contingently redeemable
warrants
$417,000
Common stock
authorized 200,000,000...
$2,602
(20.07%↑ Y/Y)
Warrant liabilities
$5,847,000
(1176.64%↑ Y/Y)
Derivative liabilities
$281,000
Accounts payable
$390,535
(-16.05%↓ Y/Y)
Accrued expenses
$345,656
(-41.97%↓ Y/Y)
Accrued series c
dividends
$32,491
Back
Back
PharmaCyte Biotech, Inc. (PMCB)
PharmaCyte Biotech, Inc. (PMCB)
Balance Sheet
Quarterly Balance Sheet for the quarter ending in 2026-07-31
source: myfinsight.com